XORTX Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
XORTX Therapeutics's earnings have been declining at an average annual rate of -30.6%, while the Pharmaceuticals industry saw earnings growing at 46% annually.
Belangrijke informatie
-30.6%
Groei van de winst
-13.0%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -54.8% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation
Aug 23
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business
Apr 01We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow
Dec 16Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth
Sep 01Opbrengsten en kosten
Hoe XORTX Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 2 | 1 |
| 31 Mar 24 | 0 | -3 | 2 | 1 |
| 31 Dec 23 | 0 | -2 | 2 | 2 |
| 30 Sep 23 | 0 | -7 | 2 | 4 |
| 30 Jun 23 | 0 | -7 | 2 | 5 |
| 31 Mar 23 | 0 | -7 | 2 | 6 |
| 31 Dec 22 | 0 | -8 | 2 | 7 |
| 30 Sep 22 | 0 | 1 | 3 | 5 |
| 30 Jun 22 | 0 | -3 | 2 | 4 |
| 31 Mar 22 | 0 | -2 | 2 | 3 |
| 01 Jan 22 | 0 | -2 | 2 | 1 |
| 30 Sep 21 | 0 | -9 | 1 | 0 |
| 30 Jun 21 | 0 | -3 | 1 | 0 |
| 31 Mar 21 | 0 | -3 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 30 Sep 19 | 0 | 0 | 0 | 0 |
| 30 Jun 19 | 0 | -1 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
| 31 Dec 18 | 0 | -3 | 1 | 0 |
| 30 Sep 18 | 0 | -3 | 1 | 0 |
| 30 Jun 18 | 0 | -3 | 1 | 0 |
| 31 Mar 18 | 0 | -3 | 1 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: XRTX is currently unprofitable.
Groeiende winstmarge: XRTX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: XRTX is unprofitable, and losses have increased over the past 5 years at a rate of 30.6% per year.
Versnelling van de groei: Unable to compare XRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: XRTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: XRTX has a negative Return on Equity (-54.83%), as it is currently unprofitable.